EUVIMEDEUVIMED entdecken
Crossref

Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker‐Strategy Designs With Multiple Treatments

Derek Dinart iD, Virginie Rondeau, Carine Bellera

Pharmaceutical Statistics · 2024

DOI: 10.1002/pst.2407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2024. Verfasst von Derek Dinart und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bordeaux Population Health Research Center, Epicene Team, U1219, University of Bordeaux, Inserm, Bordeaux, France. Hauptthemen laut MEDLINE: Biomarkers, Research Design, Models, Statistical. Die Arbeit nennt 12 Literaturangaben. Gefördert von: INSERM as part of the France Medicine Genomics (FMG) 2025 Initiative, Institut Bergonié and within the framework of the PIA3.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarker‐guided therapy is a growing area of research in medicine. To optimize the use of biomarkers, several study designs including the biomarker‐strategy design (BSD) have been proposed. Unlike traditional designs, the emphasis here is on comparing treatment strategies and not on treatment molecules as such. Patients are assigned to either a biomarker‐based strategy (BBS) arm, in which biomarker‐positive patients receive an experimental treatment that targets the identified biomarker, or a non‐biomarker‐based strategy (NBBS) arm, in which patients receive treatment regardless of their biomarker status. We proposed a simulation method based on a partially clustered frailty model (PCFM) as well as an extension of Freidlin formula to estimate the sample size required for BSD with multiple targeted treatments. The sample size was mainly influenced by the heterogeneity of treatment effect, the proportion of biomarker‐negative patients, and the randomization ratio. The PCFM is well suited for the data structure and offers an alternative to traditional methodologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersResearch DesignModels, StatisticalHumansSample SizeComputer SimulationRandomized Controlled Trials as TopicCluster Analysis

Stichwörter der Autor:innen

biomarker‐strategyfrailty modelheterogeneityrandomizedsample size

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Bordeaux Population Health Research Center, Epicene Team, U1219, University of Bordeaux, Inserm, Bordeaux, France.
  • Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.
  • Biostatistic Team, University of Bordeaux, Bordeaux, France.

ORCID-Profile: Derek Dinart

Förderung

  • INSERM as part of the France Medicine Genomics (FMG) 2025 Initiative, Institut Bergonié and within the framework of the PIA3

Zitieren

APA

Dinart, D., Rondeau, V., & Bellera, C. (2024). Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker‐Strategy Designs With Multiple Treatments. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2407

Vancouver

Dinart D, Rondeau V, Bellera C. Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker‐Strategy Designs With Multiple Treatments. Pharmaceutical Statistics. 2024. doi:10.1002/pst.2407

BibTeX
@article{Dinart2024,
  author = {Dinart, Derek and Rondeau, Virginie and Bellera, Carine},
  title = {Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker‐Strategy Designs With Multiple Treatments},
  journal = {Pharmaceutical Statistics},
  year = {2024},
  doi = {10.1002/pst.2407}
}
Kostenlos starten →